Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 16,841 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Symptom Clusters Clear all

Conditions: Delirium
Interventions: a pragmatic EEG-guided anesthetic protocol; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 60 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: HIV Infections, Hepatitis C
Interventions: highly active antiretroviral therapy (HAART); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Myelodysplastic Syndromes
Interventions: thalidomide; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 38
States / cities: La Jolla, California • Palm Springs, California • Rancho Mirage, California + 35 more

Conditions: Nocturnal Eating-Drinking Syndrome, Healthy
Interventions: Observation; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Neurodevelopmental Disorders, Intellectual Disability, Development Delay, ADHD, Autism Spectrum Disorder, Epilepsy
Interventions: Sulfonylurea; Drug
Lead sponsor: Royal Devon and Exeter NHS Foundation Trust; Other
Eligibility: 2 Years to 50 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Polycystic Ovary Syndrome
Interventions: Not listed
Lead sponsor: PCOS Challenge: The National Polycystic Ovary Syndrome Association; Other
Eligibility: 12 Years to 80 Years · Female only
Enrollment: 15,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2042
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Renal Failure Congenital, Congenital Renal Anomaly Nos, Renal Agenesis and Dysgenesis, Lower Urinary Tract Obstructive Syndrome
Interventions: Lactated Ringers Solution for Injection; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HIV Infections
Interventions: ibalizumab 800mg Q2Weeks, ibalizumab 2000mg Q4Weeks; Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infection
Interventions: T-20; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: AVX101, placebo; Biological · Other
Lead sponsor: AlphaVax, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 5
States / cities: Baltimore, Maryland • New York, New York • Rochester, New York + 2 more

Conditions: HIV/AIDS
Interventions: Not listed
Lead sponsor: Harvard School of Public Health (HSPH); Other
Eligibility: 18 Years and older
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 9
States / cities: Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 5 more

Conditions: HIV Infections
Interventions: Capravirine, Nelfinavir mesylate; Drug
Lead sponsor: Agouron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 33
States / cities: Phoenix, Arizona • Beverly Hills, California • Palm Springs, California + 25 more

Conditions: Adult Acute Promyelocytic Leukemia (M3), Blastic Phase Chronic Myelogenous Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Relapsing Chronic Myelogenous Leukemia
Interventions: bortezomib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: Ritonavir, Nelfinavir mesylate, Saquinavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2000
U.S. locations: 4
States / cities: San Francisco, California • Stanford, California • Baltimore, Maryland

Conditions: Sarcoidosis, Cancer
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Obstructive Sleep Apnea
Interventions: Patient decision aid, General sleep education; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 60 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Dry Eye Syndrome
Interventions: Preservative Free Saline, Optive, Refresh Moderate/Severe, Systane, Systane Ultra; Other
Lead sponsor: Gina Rogers; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Overweight and Obesity, Metabolic Syndrome, Weight Loss
Interventions: Signos System, Standard Lifestyle Education; Device · Other
Lead sponsor: Signos Inc; Industry
Eligibility: 22 Years and older
Enrollment: 380 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Phoenix, Arizona • Walnut Creek, California • North Miami, Florida + 2 more

Conditions: Myelodysplastic Syndrome
Interventions: Revlimid (Lenalidomide); Drug
Lead sponsor: Columbia University; Other
Eligibility: 21 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Disability, Physical Activity, Aging, Critical Illness
Interventions: Not listed
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Mucopolysaccharidosis IIIB
Interventions: SBC-103; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years to 12 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Pittsburgh, Pennsylvania

Conditions: Obesity
Interventions: Diet plus continuous bouts, Diet plus short bouts, Diet plus moderate lifestyle activity; Behavioral
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 177 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hepatitis C, Depressive Disorder, Major, Depressive Disorder, Depression, HIV Infections
Interventions: Hepatitis C educational support groups, Cognitive Behavioral Therapy skills based group sessions; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 21 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Myelodysplasia
Interventions: human myeloid progenitor cells, G-CSF; Biological · Drug
Lead sponsor: Cellerant Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 10
States / cities: La Jolla, California • San Francisco, California • Stanford, California + 7 more

Search by objective public record fields.

Electroencephalography Guidance of Anesthesia

The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin

A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes

Human Plasma Fatty Acid Oscillations

Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome

The PCOS Challenge Study

Serial Amnioinfusions as Regenerative Therapy for Pulmonary Hypoplasia

Investigator-Sponsored Protocol - Continued Use of Ibalizumab

HIV Maintenance Therapy With T-20 During HAART Interruption

Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa

Adolescent Master Protocol for Participants 18 Years of Age or Older - Lite

Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy

PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome

The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir

Association Between Cancer and Sarcoidosis

Improving Older Adults' Decision Making for OSAT

Tears Substitutions and Their Effects on Higher Order Aberrometery

Using Signos mHealth Platform in Adults for Weight Management

Revlimid in Transfusion Dependent Patients

Actigraphy to MEasuRe Intensive Care Unit Activity

Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)

Physical Activity in the Treatment of Obesity

Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia